User login
Key clinical point: Dupilumab effectively reduced signs and symptoms of atopic dermatitis (AD) along with a tolerable safety profile in a real-world setting during the COVID-19 pandemic.
Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 66.6%, 89.5%, and 95.8% patients at 16 weeks, 1 year, and 2 years of dupilumab therapy, respectively, with persistence rates being >90% throughout the 2 years of therapy. The most reported adverse events were infections, with a mild course of COVID-19 being the most reported (4.7%), followed by ocular complications (2.5%).
Study details: Findings are from a retrospective, multicenter study including 360 adults with severe AD who received ≥1 dose of dupilumab.
Disclosures: This study did not receive any funding. Some authors declared serving as a consultant, speaker, or investigator for several sources.
Source: Kojanova M et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022 (Feb 21). Doi: 10.1080/09546634.2022.2043545
Key clinical point: Dupilumab effectively reduced signs and symptoms of atopic dermatitis (AD) along with a tolerable safety profile in a real-world setting during the COVID-19 pandemic.
Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 66.6%, 89.5%, and 95.8% patients at 16 weeks, 1 year, and 2 years of dupilumab therapy, respectively, with persistence rates being >90% throughout the 2 years of therapy. The most reported adverse events were infections, with a mild course of COVID-19 being the most reported (4.7%), followed by ocular complications (2.5%).
Study details: Findings are from a retrospective, multicenter study including 360 adults with severe AD who received ≥1 dose of dupilumab.
Disclosures: This study did not receive any funding. Some authors declared serving as a consultant, speaker, or investigator for several sources.
Source: Kojanova M et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022 (Feb 21). Doi: 10.1080/09546634.2022.2043545
Key clinical point: Dupilumab effectively reduced signs and symptoms of atopic dermatitis (AD) along with a tolerable safety profile in a real-world setting during the COVID-19 pandemic.
Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 66.6%, 89.5%, and 95.8% patients at 16 weeks, 1 year, and 2 years of dupilumab therapy, respectively, with persistence rates being >90% throughout the 2 years of therapy. The most reported adverse events were infections, with a mild course of COVID-19 being the most reported (4.7%), followed by ocular complications (2.5%).
Study details: Findings are from a retrospective, multicenter study including 360 adults with severe AD who received ≥1 dose of dupilumab.
Disclosures: This study did not receive any funding. Some authors declared serving as a consultant, speaker, or investigator for several sources.
Source: Kojanova M et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022 (Feb 21). Doi: 10.1080/09546634.2022.2043545